Short answer
Bioventus Inc. (BVS) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 28, 2026. Quarterly revenue was $132M (up 6.6% year over year) with net income of $3M.
Q1 2026 key financials · XBRL
- Revenue
- $132M
- +6.6% YoY
- Net income
- $3M
- +218.1% YoY
- Operating margin
- 6.4%
- Gross margin
- 68.7%
- EPS (diluted)
- $0.04
- +200.0% YoY
Source: XBRL data from the Bioventus Inc. (BVS) Q1 2026 10-Q on SEC EDGAR. USD.
Bioventus Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $132.1M, up 6.6% YoY from $123.9M
- Operating margin 6.4% vs 3.9% YoY; gross margin 68.7% vs 67.0%
- Best segment International Surgical Solutions, sales $5.5M, up 25.0% YoY
- Worst product line U.S. KOA, HA volume down 1.7% despite favorable rebates
- $22.0M discretionary term-loan prepayment; revolver availability $98.4M
- Management cited sufficient liquidity for twelve months; rebate volumes and compensation costs remained headwinds
Risk Factors
- No material risk-factor changes from the 2025 10-K
- Carried-forward risks could materially affect business, financial condition, or future results
- Additional unknown or currently immaterial risks could adversely affect results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bioventus Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.